Analyst Ratings For AMAG Pharmaceuticals (NASDAQ:AMAG)
Today, B. Riley raised its price target on AMAG Pharmaceuticals (NASDAQ:AMAG) to $23.00 per share.
Some recent analyst ratings include
- 3/5/2018-Jefferies Group was Downgraded by analysts at Jefferies Group from a “Buy ” rating to a ” Hold” rating. They now have a $20.00 price target on the stock, up previously from $21.00 .
- 3/1/2018-Piper Jaffray Companies Reiterated Rating of Hold.
- 2/27/2018-Cowen Reiterated Rating of Hold.
- 2/27/2018-Cantor Fitzgerald Reiterated Rating of Hold.
- 2/15/2018-Janney Montgomery Scott Upgrade from a “Neutral ” rating to a ” Buy” rating.
- On 3/6/2018 Joseph Vittiglio, EVP, sold 770 with an average share price of $20.80 per share and the total transaction amounting to $16,016.00.
- On 8/29/2017 Joseph Vittiglio, SVP, sold 1,250 with an average share price of $16.75 per share and the total transaction amounting to $20,937.50.
- On 7/13/2017 Julie Krop, SVP, sold 4,938 with an average share price of $20.00 per share and the total transaction amounting to $98,760.00.
- On 5/1/2017 Julie Krop, SVP, sold 1,891 with an average share price of $24.45 per share and the total transaction amounting to $46,234.95.
- On 10/20/2016 Julie Krop, SVP, sold 4,938 with an average share price of $24.80 per share and the total transaction amounting to $122,462.40.
- On 11/10/2015 John A Fallon, Director, bought 3,230 with an average share price of $31.20 per share and the total transaction amounting to $100,776.00.
- On 10/1/2015 William K Heiden, CEO, sold 2,000 with an average share price of $39.69 per share and the total transaction amounting to $79,380.00.
Recent Trading Activity for AMAG Pharmaceuticals (NASDAQ:AMAG)
Shares of AMAG Pharmaceuticals closed the previous trading session at with 20.350000381469727 shares trading hands.